Claudine Isaacs, MD, on the Limitations of At-Home Genetic Tests for Hereditary Breast/Ovarian Cancers

More than 95% of BRCA1 or BRCA1 pathogenic variants would have been missed by DTC testing, largest such study showed

November 8, 2023 9:00 am

By Mark Fuerst

Direct-to-consumer (DTC) genetic testing has limited use as a screening tool for identifying individuals at risk of hereditary breast or ovarian cancer, especially in those of non-Ashkenazi Jewish descent, researchers reported.

Most current DTC genetic tests evaluate … Read more

T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers

November 7, 2023 9:00 am

RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer

November 5, 2023 9:00 am

Clearity’s Perspective: The combination of avutometinib and defactinib has shown encouraging activity in Low-Grade Serous Ovarian Cancer. Updated results from the RAMP 201 trial suggest that the combination is active regardless of the number of prior therapies patients have received. Read more

Celebrating Life While Honoring Death: Q&A with our Oncology Chaplain, Michael Eselun

October 20, 2023 9:00 am

Michael Eselun, Clearity’s Oncology Chaplain, sat down with our Director of Education, Danielle Peterson, to discuss what occasions like the Jewish New Year Celebration, Rosh Hashanah, and Día de los Muertos can teach us about the role the contemplation of … Read more

Liquid Biopsy Shows Promise to Distinguish Benign Pelvic Masses from Tumorous Ones

October 11, 2023 9:00 am

A new liquid biopsy test developed by researchers at USC Norris Comprehensive Cancer Center has shown promise to distinguish which pelvic masses are benign and which are tumorous, a development that could aid early diagnosis of high-grade serous ovarian carcinoma … Read more

Phase 3 Trial of TTFields and Paclitaxel Misses OS End Point in Ovarian Cancer

August 28, 2023 9:00 am

The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.

Patients with platinum-resistant ovarian cancer given tumor treating fields

Read more

Batiraxcept Plus Paclitaxel Misses PFS End Point in Platinum-Resistant Ovarian Cancer

August 3, 2023 9:00 am

The addition of batiraxcept to paclitaxel did not significantly improve progression-free survival compared with paclitaxel alone in a prespecified subset of patients with platinum-resistant ovarian cancer who were not previously exposed to bevacizumab, missing the primary end point of the Read more

Aerobic exercise may reduce chemotherapy-induced peripheral neuropathy in ovarian cancer

August 2, 2023 9:00 am

Key takeaways:

  • Women assigned a 6-month intervention reported decreased chemotherapy-induced peripheral neuropathy symptoms.
  • Women in the control group reported a slight increase in symptoms.

A 6-month aerobic exercise intervention significantly improved self-reported chemotherapy-induced peripheral neuropathy among women who underwent chemotherapy … Read more

Upifitamab Rilsodotin Fails to Meet ORR End Point in NaPi2b+ Platinum-Resistant Ovarian Cancer

July 27, 2023 9:00 am

The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.

 

The phase 1/2 UPLIFT trial (NCT03319628) … Read more

Avutometinib Plus Defactinib Demonstrates Promising Activity in Recurrent LGSOC

June 6, 2023 7:03 am

Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the … Read more

ImmunoGen’s Elahere Doubles Response Rate Versus Chemo in Phase III Ovarian Cancer Trial

June 4, 2023 9:30 pm

CHICAGO – Twice as many patients with folate receptor alpha (FRα)-positive, advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer responded to ImmunoGen’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) than did patients on chemotherapy in a confirmatory Phase III trial.… Read more

Tumor Testing May Be Increasingly Useful in Ovarian Cancer

May 8, 2023 3:00 pm

Testing tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.

Among 1,092 patients with ovarian cancer, 27.5% underwent next-generation sequencing; 96.1% had one or more genetic alteration; 25.9% had an alteration that aligned with targeted treatment

In an

Read more

Fred Hutch study highlights racial disparities in ovarian cancer risk for women

May 4, 2023 2:48 pm

Researchers examined risks for Black and white women with endometriosis and fibroids to understand how common medical interventions for those conditions modified the outcomes

SEATTLE, WA — May 4, 2023 — A new Fred Hutchinson Cancer Center study in the

Read more

Financial Navigation Can Reduce the Financial Toxicity of Cancer Care

April 21, 2023 9:00 am

Clearity’s Perspective: Ask your health care team if they have a social worker, financial navigator, patient navigator, or nurse navigator who can help you manage the financial impacts of cancer. See Clearity’s Information and Support Resources for national organizations that Read more

Exome sequencing identifies cancer predisposition-gene carriers screening guidelines miss

April 19, 2023 12:55 pm

by Jennifer Southall

Whole-exome sequencing identified carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome who, under current guidelines, would not have qualified for genetic testing, according to study results.

The findings, presented at American Association … Read more

1 in 4 patients at gynecologic oncology clinic lack adequate cancer health literacy

March 29, 2023 9:55 am

by Matthew Shinkle

One of every four patients with a gynecologic oncology office visit had inadequate levels of cancer health literacy, according to data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Researchers found racial and ethnic … Read more

Ovarian Cancer in Black and African American Communities

February 3, 2023 3:10 pm

Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed Read more

Luveltamab Tazevibulin Shows Encouraging Activity in Frα-Selected Advanced Ovarian Cancer

January 16, 2023 10:07 am

by Caroline Seymour

Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.

Treatment with the folate receptor

Read more

Machine learning model builds on imaging methods to better detect ovarian lesions

November 29, 2022 11:37 am
by Beth Miller
(From left) The top row shows an ultrasound image of a malignant lesion, the blood oxygen saturation, and hemoglobin concentration. The bottom row is an ultrasound image of a benign lesion, the blood oxygen saturation, and hemoglobin
Read more